Literature DB >> 12703961

Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

J Matthew Hutzler1, Gregory S Walker, Larry C Wienkers.   

Abstract

Several pharmacophore models have suggested that substrates and inhibitors of cytochrome P450 2D6 (P450 2D6) possess a nitrogen with a positive charge that participates in a charge-pair interaction with the aspartate 301 residue. In an effort to investigate this paradigm for P450 2D6 binding, an analogue series of the stereoisomers quinidine and quinine were synthesized and screened for binding affinity as measured by inhibition. Results revealed that bulky substituents added to the quinuclidine nitrogen (quaternary salts) did not affect the inhibitory potency of quinidine (IC(50) = 0.02 microM), suggesting minimal contribution to binding affinity of this inhibitor by the purported ionic-binding interaction. Meanwhile, substantial decreases in inhibitory potency were observed for the N-methyl, N-ethyl, and N-benzyl quininium salts, suggesting that the quaternary nitrogen of this antipode interacts with a distinct region of the P450 2D6 active site as compared to the corresponding nitrogen of quinidine. Interestingly, esterification of quinidine resulted in a substantial loss of inhibitory potency, likely due to disruption of a hydrogen-bonding interaction of the hydroxyl group. This suggests that hydrogen bonding contributes more to the tight binding of quinidine than does the charge-pair interaction of the positively charged nitrogen. Moreover, benzoyl ester formation of quinine caused the binding orientation to switch from type II to type I, with concomitant restoration of P450 2D6 inhibitory potency. Thus, it appears that both hydrogen bonding and the ionic interaction of the basic nitrogen of quinine contribute to inhibitory potency, while the hydroxyl group also apparently contributes to directing type II binding. Overall, results suggest that when analyzing a series of compounds that include stereoisomers for development of predictive pharmacophore/protein models describing P450 2D6 binding, it may be inappropriate to assume that the ionic interaction of the basic nitrogen with aspartate 301 represents the primary binding interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12703961     DOI: 10.1021/tx025674x

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  13 in total

1.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

2.  Temperature-dependent time-resolved fluorescence study of cinchonine alkaloid dication.

Authors:  Hirdyesh Mishra; Sanjay Pant; Hera B Tripathi
Journal:  J Fluoresc       Date:  2007-08-23       Impact factor: 2.217

3.  Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.

Authors:  Sunetra Ray; Peter B Madrid; Paul Catz; Susanna E LeValley; Michael J Furniss; Linda L Rausch; R Kiplin Guy; Joseph L DeRisi; Lalitha V Iyer; Carol E Green; Jon C Mirsalis
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

4.  Lead optimization of antimalarial propafenone analogues.

Authors:  David Lowes; Anupam Pradhan; Lalitha V Iyer; Toufan Parman; Jason Gow; Fangyi Zhu; Anna Furimsky; Andrew Lemoff; W Armand Guiguemde; Martina Sigal; Julie A Clark; Emily Wilson; Liang Tang; Michele C Connelly; Joseph L Derisi; Dennis E Kyle; Jon Mirsalis; R Kiplin Guy
Journal:  J Med Chem       Date:  2012-06-29       Impact factor: 7.446

5.  Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.

Authors:  An Wang; C David Stout; Qinghai Zhang; Eric F Johnson
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

6.  Rolapitant Is a Reversible Inhibitor of CYP2D6.

Authors:  Sarah M Glass; Sabrina M Leddy; Michael C Orwin; Garret P Miller; Kyle A Furge; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2019-04-05       Impact factor: 3.922

7.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

Review 8.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

9.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jul-Sep       Impact factor: 2.441

Review 10.  Inhibitors of connexin and pannexin channels as potential therapeutics.

Authors:  Joost Willebrords; Michaël Maes; Sara Crespo Yanguas; Mathieu Vinken
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.